• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Incidence and prevalence of inflammatory bowel disease in Devon, UK.英国德文郡炎症性肠病的发病率和患病率
Frontline Gastroenterol. 2020 Jun 24;12(6):461-470. doi: 10.1136/flgastro-2019-101369. eCollection 2021.
2
Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study.巴西公共医疗系统中炎症性肠病流行病学的时间趋势:一项基于大量人群的研究。
Lancet Reg Health Am. 2022 Jun 9;13:100298. doi: 10.1016/j.lana.2022.100298. eCollection 2022 Sep.
3
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.2018年炎症性肠病对加拿大的影响:直接成本与医疗服务利用情况
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
4
East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.欧洲炎症性肠病发病率的东西梯度:ECCO-EpiCom 起始队列。
Gut. 2014 Apr;63(4):588-97. doi: 10.1136/gutjnl-2013-304636. Epub 2013 Apr 20.
5
A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.一项针对马来西亚吉隆坡单一三级医疗中心炎症性肠病患者发病率趋势、社会人口学和临床特征的四十年分析。
BMC Public Health. 2019 Jun 13;19(Suppl 4):550. doi: 10.1186/s12889-019-6858-2.
6
Epidemiology of Inflammatory Bowel Disease in Southern Peninsular Malaysia.马来西亚南部半岛炎症性肠病的流行病学
Med J Malaysia. 2018 Apr;73(2):86-89.
7
Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010.1970年至2010年明尼苏达州奥尔姆斯特德县克罗恩病和溃疡性结肠炎的发病率及患病率
Clin Gastroenterol Hepatol. 2017 Jun;15(6):857-863. doi: 10.1016/j.cgh.2016.10.039. Epub 2016 Nov 14.
8
Incidence and prevalence of inflammatory bowel diseases in gastroenterology primary care setting.炎症性肠病在胃肠病初级保健环境中的发病率和流行率。
Eur J Intern Med. 2013 Dec;24(8):852-6. doi: 10.1016/j.ejim.2013.06.005. Epub 2013 Jul 16.
9
Prevalence of Inflammatory Bowel Disease Unclassified, as Estimated Using the Revised Porto Criteria, among Korean Pediatric Patients with Inflammatory Bowel Disease.采用修订后的波尔图标准估算韩国炎症性肠病儿科患者中未分类炎症性肠病的患病率。
Pediatr Gastroenterol Hepatol Nutr. 2024 Jul;27(4):206-214. doi: 10.5223/pghn.2024.27.4.206. Epub 2024 Jul 8.
10
Inflammatory bowel disease incidence, prevalence and 12-month initial disease course in Tasmania, Australia.澳大利亚塔斯马尼亚的炎症性肠病发病率、患病率和 12 个月初始疾病进程。
Intern Med J. 2019 May;49(5):622-630. doi: 10.1111/imj.14111.

引用本文的文献

1
Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study.乌帕替尼在克罗恩病中的真实世界疗效:一项英国多中心回顾性队列研究。
Frontline Gastroenterol. 2024 Jul;15(4):297-304. doi: 10.1136/flgastro-2024-102668. Epub 2024 Apr 3.
2
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine.定义克罗恩病和溃疡性结肠炎对先进治疗方法反应的预测因素:精准医学中 IBD-RESPONSE 和嵌套 CD-metaRESPONSE 前瞻性、多中心、观察性队列研究的方案。
BMJ Open. 2024 Apr 17;14(4):e073639. doi: 10.1136/bmjopen-2023-073639.
3
Pleiotropic Effects of Vitamin D in Patients with Inflammatory Bowel Diseases.维生素D在炎症性肠病患者中的多效性作用
J Clin Med. 2022 Sep 27;11(19):5715. doi: 10.3390/jcm11195715.
4
Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients.炎症性肠病患者报告的质量评估应推动服务改善:英国 IBD 单位和患者的全国调查。
Aliment Pharmacol Ther. 2022 Aug;56(4):625-645. doi: 10.1111/apt.17042. Epub 2022 Jun 1.
5
Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?了解抗 TNF 治疗失败:在生物初治的活动性腔型克罗恩病患者中,血清三碘甲状腺原氨酸/甲状腺素(T3/T4)比值是否可预测抗 TNF 治疗的疗效?
Aliment Pharmacol Ther. 2022 Sep;56(5):783-793. doi: 10.1111/apt.17089. Epub 2022 Jun 29.
6
The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.精准医学在预测炎症性肠病结局和控制组织重塑中的未来。
Gastroenterology. 2022 Apr;162(5):1525-1542. doi: 10.1053/j.gastro.2021.09.077. Epub 2022 Jan 4.
7
Current Use of EEN in Pre-Operative Optimisation in Crohn's Disease.EEN 在克罗恩病术前优化中的当前应用。
Nutrients. 2021 Dec 8;13(12):4389. doi: 10.3390/nu13124389.
8
The incidence and prevalence of inflammatory bowel disease in UK primary care: a retrospective cohort study of the IQVIA Medical Research Database.英国初级医疗中炎症性肠病的发病率和患病率:一项对艾昆纬医学研究数据库的回顾性队列研究
BMC Gastroenterol. 2021 Mar 26;21(1):139. doi: 10.1186/s12876-021-01716-6.
9
Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.炎症性肠病患者结直肠癌漏诊的根本原因分析。
Aliment Pharmacol Ther. 2021 Jan;53(2):291-301. doi: 10.1111/apt.16155. Epub 2020 Nov 7.

本文引用的文献

1
A Systematic Review and Meta-analysis of Paediatric Inflammatory Bowel Disease Incidence and Prevalence Across Europe.一项在欧洲范围内对儿童炎症性肠病发病率和流行率进行的系统评价和荟萃分析。
J Crohns Colitis. 2020 Sep 7;14(8):1119-1148. doi: 10.1093/ecco-jcc/jjaa037.
2
Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis.粪便钙卫蛋白检测用于识别有器质性胃肠道疾病的患者:系统评价和荟萃分析。
Med J Aust. 2019 Nov;211(10):461-467. doi: 10.5694/mja2.50384. Epub 2019 Nov 3.
3
Fine-scale geographical distribution and ecological risk factors for Crohn's disease in France (2007-2014).法国(2007-2014 年)克罗恩病的精细地理分布和生态风险因素。
Aliment Pharmacol Ther. 2020 Jan;51(1):139-148. doi: 10.1111/apt.15512. Epub 2019 Oct 6.
4
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.英国胃肠病学会成人炎症性肠病管理共识指南。
Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.
5
IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology.苏格兰洛锡安区基于捕捉-再捕获法推算的 IBD 患病率。
Gut. 2019 Nov;68(11):1953-1960. doi: 10.1136/gutjnl-2019-318936. Epub 2019 Jul 11.
6
The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years.炎症性肠病医疗利用和费用的十年演变。
J Crohns Colitis. 2019 May 27;13(6):744-754. doi: 10.1093/ecco-jcc/jjz003.
7
Mortality Risk of Inflammatory Bowel Disease: A Case-Control Study of New York State Death Records.炎症性肠病的死亡率:纽约州死亡记录的病例对照研究。
Dig Dis Sci. 2019 Jun;64(6):1604-1611. doi: 10.1007/s10620-018-5430-8. Epub 2019 Jan 2.
8
Illness-Death Model in Chronic Disease Epidemiology: Characteristics of a Related, Differential Equation and an Inverse Problem.慢性病流行病学中的疾病-死亡模型:一个相关微分方程和一个反问题的特征
Comput Math Methods Med. 2018 Sep 12;2018:5091096. doi: 10.1155/2018/5091096. eCollection 2018.
9
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.21 世纪全球炎症性肠病的发病率和流行率:基于人群的系统综述研究。
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.
10
A UK cost of care model for inflammatory bowel disease.英国炎症性肠病护理成本模型。
Frontline Gastroenterol. 2015 Jul;6(3):169-174. doi: 10.1136/flgastro-2014-100514. Epub 2015 Feb 24.

英国德文郡炎症性肠病的发病率和患病率

Incidence and prevalence of inflammatory bowel disease in Devon, UK.

作者信息

Hamilton Ben, Green Harry, Heerasing Neel, Hendy Peter, Moore Lucy, Chanchlani Neil, Walker Gareth, Bewshea Claire, Kennedy Nicholas A, Ahmad Tariq, Goodhand James

机构信息

Exeter IBD Pharmacogenetics Research Group, University of Exeter, Exeter, UK.

Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, Devon, UK.

出版信息

Frontline Gastroenterol. 2020 Jun 24;12(6):461-470. doi: 10.1136/flgastro-2019-101369. eCollection 2021.

DOI:10.1136/flgastro-2019-101369
PMID:34712463
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8515282/
Abstract

BACKGROUND AND AIMS

We sought to define temporal changes in prevalence of inflammatory bowel disease (IBD) in East Devon, UK, in order to facilitate service planning over the next 5 years.

METHODS

Multiple primary and secondary care databases were used to identify and verify cases. Point prevalence and incidence of IBD were reported in April 2017 and from 2008 to 2016, respectively. Future prevalence and healthcare activity requirements were estimated by linear regression.

RESULTS

Prevalence of ulcerative colitis (UC), Crohn's disease (CD) and inflammatory bowel disease unclassified (IBDU) were 479.72, 265.94 and 35.34 per 100 000 persons, respectively. In 2016, the incidence rates of UC, CD and IBDU were 15.4, 10.7 and 1.4 per 100 000 persons per year, respectively. There were no significant changes in the incidence of CD (p=0.49, R=0.26) or UC (p=0.80, R=0.10). IBD prevalence has increased by 39.9% (95% CI 28.2 to 53.7) in the last 10 years without differences in the rate of change between UC and CD. Overall, 27% of patients were managed in primary care, a quarter of whom were eligible but not receiving endoscopic surveillance. Outpatient clinics, MRI and biologic use, but not helpline calls, admissions, or surgeries increased over and above the change in IBD prevalence.

CONCLUSIONS

We report one of the highest prevalence and incidence rates of IBD from Northern Europe. Overall, IBD incidence is static, but prevalence is increasing. We estimate that 1% of our population will live with IBD between 2025 and 2030.

摘要

背景与目的

我们试图确定英国东德文郡炎症性肠病(IBD)患病率的时间变化情况,以便为未来5年的服务规划提供便利。

方法

利用多个初级和二级医疗数据库来识别和核实病例。分别报告了2017年4月以及2008年至2016年IBD的时点患病率和发病率。通过线性回归估计未来患病率和医疗活动需求。

结果

溃疡性结肠炎(UC)、克罗恩病(CD)和未分类的炎症性肠病(IBDU)的患病率分别为每10万人479.72例、265.94例和35.34例。2016年,UC、CD和IBDU的发病率分别为每年每10万人15.4例、10.7例和1.4例。CD(p = 0.49,R = 0.26)或UC(p = 0.80,R = 0.10)的发病率没有显著变化。在过去10年中,IBD患病率增加了39.9%(95%置信区间为28.2至53.7),UC和CD之间的变化率没有差异。总体而言,27%的患者在初级医疗中接受管理,其中四分之一符合条件但未接受内镜监测。门诊诊所、磁共振成像(MRI)和生物制剂的使用有所增加,但求助热线电话、住院或手术的增加幅度并未超过IBD患病率的变化。

结论

我们报告了北欧IBD的最高患病率和发病率之一。总体而言,IBD发病率稳定,但患病率在上升。我们估计,在2025年至2030年期间,我们人口中有1%将患有IBD。